• AKANKSHA DWIVEDI Acropolis Institute of Pharmaceutical Education and Research, Indore, MP, 2KIET Group of Institutions (KIET School of Pharmacy), Delhi-NCR, Meerut Road (NH-58), Ghaziabad 201206
  • RAKHI KHABIYA Acropolis Institute of Pharmaceutical Education and Research, Indore, MP, 2KIET Group of Institutions (KIET School of Pharmacy), Delhi-NCR, Meerut Road (NH-58), Ghaziabad 201206
  • ALANKAR SHRIVASTAVA Acropolis Institute of Pharmaceutical Education and Research, Indore, MP, 2KIET Group of Institutions (KIET School of Pharmacy), Delhi-NCR, Meerut Road (NH-58), Ghaziabad 201206
  • SIDDHARTH TYAGI Acropolis Institute of Pharmaceutical Education and Research, Indore, MP, 2KIET Group of Institutions (KIET School of Pharmacy), Delhi-NCR, Meerut Road (NH-58), Ghaziabad 201206
  • KANDASAMY NAGARAJAN Acropolis Institute of Pharmaceutical Education and Research, Indore, MP, 2KIET Group of Institutions (KIET School of Pharmacy), Delhi-NCR, Meerut Road (NH-58), Ghaziabad 201206
  • G. N. DARWHEKAR Acropolis Institute of Pharmaceutical Education and Research, Indore, MP, 2KIET Group of Institutions (KIET School of Pharmacy), Delhi-NCR, Meerut Road (NH-58), Ghaziabad 201206



Cabozantinib, cancer, analytical methods, spectrophotometry, chromatography


Globally, the burden of cancer is substantial and growing. The impact of burden of such diseases over the society is unpredictable in terms of health lost and cost. Unfortunately, the estimates shown the burden may be increasing in upcoming decades. Cabozantinib (CBZ) is newly developed tyrosin kinase inhibitor (TKI) for Differentiated thyroid cancer (DTC), Hepatic Cellular Carcinoma (HCC), Medullary thyroid cancer (MTC) and Renal Cell Carcinoma (RCC). The objective of presented review is to provide updated knowledge of drug especially covering analytical methodologies. The review covered introduction, mechanism of action, pharmacokinetics, synthesis and developed analytical methods by various researchers. The review covered one spectrophotometry and about twenty chromatography methods. The review will be helpful for the scientist working in this area and especially helpful for analytical scientists exploring new analytical methodologies for CBZ.


Download data is not yet available.


Herbrink M, Nuijen B, Schellens JH, Beijnen JH. Variability in bioavailability of small molecular tyrosine kinase inhibitors. Cancer Treat Rev. 2015;41(5):412-22. doi: 10.1016/j.ctrv.2015.03.005. PMID: 25818541.

Cancer [Internet], World Health Organization. [Updated 2022 Feb 03; Cited 2022 Sept 09]. Available from:,Cancer%20is%20a%20leading%20cause%20of%20death%20worldwide%2C%20accounting%20for,lung%20(2.21%20million%20cases)%3B.

Hausman DM. What Is Cancer? Perspect Biol Med. 2019;62(4):778-784. doi: 10.1353/pbm.2019.0046. PMID: 31761807.

Roy PS, Saikia BJ. Cancer and cure: A critical analysis. Indian J Cancer. 2016 Jul-Sep;53(3):441-442. doi: 10.4103/0019-509X.200658. PMID: 28244479.

National Cancer Institute at the National Institutes of Health [Internet] [Updated 2020 Sept 25; Cited 2022 June 27] Available from:

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424. doi: 10.3322/caac.21492. PMID: 30207593.

Maxwell JE, Sherman SK, O'Dorisio TM, Howe JR. Medical management of metastatic medullary thyroid cancer. Cancer. 2014;120(21):3287-301. doi: 10.1002/cncr.28858. PMID: 24942936.

Priya SR, Dravid CS, Digumarti R, Dandekar M. Targeted Therapy for Medullary Thyroid Cancer: A Review. Front Oncol. 2017;7:238. doi: 10.3389/fonc.2017.00238. PMID: 29057215.

Hsieh JJ, Purdue MP, Signoretti S, Swanton C, Albiges L, Schmidinger M, Heng DY, Larkin J, Ficarra V. Renal cell carcinoma. Nat Rev Dis Primers. 2017;3:17009. doi: 10.1038/nrdp.2017.9. PMID: 28276433

Elisei R, Schlumberger MJ, Müller SP, Schöffski P, Brose MS, Shah MH, Licitra L, Jarzab B, Medvedev V, Kreissl MC, Niederle B, Cohen EE, Wirth LJ, Ali H, Hessel C, Yaron Y, Ball D, Nelkin B, Sherman SI. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol. 2013;31(29):3639-46. doi: 10.1200/JCO.2012.48.4659. PMID: 24002501

Schlumberger M, Elisei R, Müller S, Schöffski P, Brose M, Shah M, Licitra L, Krajewska J, Kreissl MC, Niederle B, Cohen EEW, Wirth L, Ali H, Clary DO, Yaron Y, Mangeshkar M, Ball D, Nelkin B, Sherman S. Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma. Ann Oncol. 2017;28(11):2813-2819. doi: 10.1093/annonc/mdx479. PMID: 29045520.

Villanueva A. Hepatocellular Carcinoma. N Engl J Med 2019; 380:1450-1462

doi: 10.1056/NEJMra1713263.

Veerman GDM, Hussaarts KGAM, Jansman FGA, Koolen SWL, van Leeuwen RWF, Mathijssen RHJ. Clinical implications of food-drug interactions with small-molecule kinase inhibitors. Lancet Oncol. 2020;21(5):e265-e279. doi: 10.1016/S1470-2045(20)30069-3.

Dimitroulis D, Damaskos C, Valsami S, Davakis S, Garmpis N, Spartalis E, Athanasiou A, Moris D, Sakellariou S, Kykalos S, Tsourouflis G, Garmpi A, Delladetsima I, Kontzoglou K, Kouraklis G. From diagnosis to treatment of hepatocellular carcinoma: An epidemic problem for both developed and developing world. World J Gastroenterol. 2017 Aug 7;23(29):5282-5294. doi: PMID: 28839428.

Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018 Mar 31;391(10127):1301-1314. doi: 10.1016/S0140-6736(18)30010-2. PMID: 29307467.

Chahrour O, Cairns D, Omran Z. Small molecule kinase inhibitors as anti-cancer therapeutics. Mini Rev Med Chem. 2012;12(5):399-411. doi: 10.2174/138955712800493915. PMID: 22303944.

Yakes FM, Chen J, Tan J, Yamaguchi K, Shi Y, Yu P, Qian F, Chu F, Bentzien F, Cancilla B, Orf J, You A, Laird AD, Engst S, Lee L, Lesch J, Chou YC, Joly AH. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther. 2011;10(12):2298-308. doi: 10.1158/1535-7163.MCT-11-0264. PMID: 21926191.

Liu H, Sun S, Wang G, Lu M, Zhang X, Wei X, Gao X, Huang C, Li Z, Zheng J, Zhang Q. Tyrosine Kinase Inhibitor Cabozantinib Inhibits Murine Renal Cancer by Activating Innate and Adaptive Immunity. Front Oncol. 2021;11:663517. doi: 10.3389/fonc.2021.663517. PMID: 33954115.

Cabozantinib-S-Malate. [Internet] National Cancer Institute. [Cited 2022 Sept 09]. Available from:

PubChem [Internet]. Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information; 2004-. PubChem Compound Summary for CID 25102847, Cabozantinib; [cited 2022 Sept. 17]. Available from:

Food and Drug Administration. [Internet] CDER clinical pharmacology and biophamaceutics reviews[s] for cabozantinib [COMETRIQ]; 2012. [cited 2022 Sept. 17]. Available from:

Lacy SA, Miles DR, Nguyen LT. Clinical Pharmacokinetics and Pharmacodynamics of Cabozantinib. Clin Pharmacokinet. 2017;56(5):477-491. doi: 10.1007/s40262-016-0461-9. PMID: 27734291.

Schmidinger M, Danesi R. Management of Adverse Events Associated with Cabozantinib Therapy in Renal Cell Carcinoma. Oncologist. 2018;23(3):306-315. doi: 10.1634/theoncologist.2017-0335. PMID: 29146618

Patel A. Benign vs Malignant Tumors. JAMA Oncol. 2020;6(9):1488. doi:10.1001/jamaoncol.2020.2592. PMID: 32729930.

Bhullar KS, Lagarón NO, McGowan EM, Parmar I, Jha A, Hubbard BP, Rupasinghe HPV. Kinase-targeted cancer therapies: progress, challenges and future directions. Mol Cancer. 2018;17(1):48. doi: 10.1186/s12943-018-0804-2. PMID: 29455673

Roskoski R Jr. Properties of FDA-approved small molecule protein kinase inhibitors: A 2022 update. Pharmacol Res. 2022;175:106037. doi: 10.1016/j.phrs.2021.106037. PMID: 34921994.

Damghani T, Moosavi F, Khoshneviszadeh M, Mortazavi M, Pirhadi S, Kayani Z, Saso L, Edraki N, Firuzi O. Imidazopyridine hydrazone derivatives exert antiproliferative effect on lung and pancreatic cancer cells and potentially inhibit receptor tyrosine kinases including c-Met. Sci Rep. 2021;11(1):3644. doi: 10.1038/s41598-021-83069-4.

Roskoski R Jr. Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes. Pharmacol Res. 2016;103:26-48. doi: 10.1016/j.phrs.2015.10.021. PMID: 33574356.

Hara T, Kimura A, Miyazaki T, Tanaka H, Morimoto M, Nakai K, Soeda J. Cabozantinib inhibits AXL- and MET-dependent cancer cell migration induced by growth-arrest-specific 6 and hepatocyte growth factor. Biochem Biophys Rep. 2020;21:100726. doi: 10.1016/j.bbrep.2020.100726. PMID: 32055714.

Naresh GKRS, Guruprasad L. Enhanced metastable state models of TAM kinase binding to cabozantinib explains the dynamic nature of receptor tyrosine kinases. J Biomol Struct Dyn. 2021;39(4):1213-1235. doi: 10.1080/07391102.2020.1730968. PMID: 32070235.

Grüllich C. Cabozantinib: a MET, RET, and VEGFR2 tyrosine kinase inhibitor. Recent Results Cancer Res. 2014;201:207-14. doi: 10.1007/978-3-642-54490-3_12. PMID: 24756794.

Wiechno P, Kucharz J, Sadowska M, Michalski W, Sikora-Kupis B, Jonska-Gmyrek J, Poniatowska G, Nietupski K, Ossolinski K, Demkow T. Contemporary treatment of metastatic renal cell carcinoma. Med Oncol. 2018;35(12):156. doi: 10.1007/s12032-018-1217-1. PMID: 30368624.

Lacy S, Yang B, Nielsen J, Miles D, Nguyen L, Hutmacher M. A population pharmacokinetic model of cabozantinib in healthy volunteers and patients with various cancer types. Cancer Chemother Pharmacol. 2018;81(6):1071–82. doi: PMID: 29687244.

Benzaghou F, Nguyen TXQ, Lacy S. Pharmacokinetics of cabozantinib in Asian and non-Asian populations. Ann Oncol. 2018;29(Supplement 9):ix74. doi:

Gerner B, Scherf-Clavel O. Physiologically based pharmacokinetic modelling of cabozantinib to simulate enterohepatic recirculation, drug–drug interaction with rifampin and liver impairment. Pharmaceutics. 2021;13(6):778. doi: 10.3390/pharmaceutics13060778. PMID: 34067429.

Cerbone L, Combarel D, Geraud A, Auclin E, Foulon S, Alves Costa Silva C, Colomba E, Carril L, Derosa L, Flippot R, Mir O, Khoudour N, Blanchet B, Escudier B, Paci A, Albiges L. Association of cabozantinib pharmacokinetics, progression and toxicity in metastatic renal cell carcinoma patients: results from a pharmacokinetics/pharmacodynamics study. ESMO Open. 2021;6(6):100312. doi: 10.1016/j.esmoop.2021.100312.

European Medicines Agency. Assessment report - CHMP assessment report on Cabometyx. Proced No EMEA/H/C/004163/0000. 2016;EMA/664123(September):1–199.

Ding HX, Leverett CA, Kyne RE Jr, Liu KK, Sakya SM, Flick AC, O'Donnell CJ. Synthetic approaches to the 2012 new drugs. Bioorg Med Chem. 2014;22(7):2005-32. doi: 10.1016/j.bmc.2014.02.017.

Fang R, Wang B, Zhao Z, Yin L, Wang H, Xu J. A New Synthesis of Cabozantinib. Org. Prep. Proced. Int., 2019;51(4):381-387. doi: 10.1080/00304948.2019.1615362

Boyer S, Cantin D, Sidney X. Pyridonecarboxamide derivatives useful in treating hyper proliferative and angiogenesis disorders. WO2008/048375A1, Publication date. 24.04.2008.

Di Pietro LV, Harmange J, Daniel BC, Germain EJ, Habgood GJ, Kim JL, Patel VF, Potashman M, van der Plas S. Heterocyclic compounds and methods of use. US 7,531,553 B2, Date of Patent: May 12, 2009.

Ann WJ, Sriram N, Matthew P, Neil A. Process of preparing quinoline derivatives. WO2013/059788A1, Publication date 25.04.2013.

Aftab DT. A dual Met-Vfgf modulator for treating osteolytic bone metastases. WO2013/166296A1, Publication date: 07.11.2013.

Srinivasan TR, Sajja E, Gogulapati VPR, Sagyam RR, Gandham SKB, Rajesham B. The process for the preparation of N-(4-(6,7-Dimethoxyquinolin-4-yloxy)phenyl)-N’’-(4-fluorophenyl)cyclopropane-1, 1-dicarboxamide, (2S)-hydroxybutanedioate and its polymorphs thereof. PCT/IN2017/000139. Publication date: 06.12.2017. [cited 2022 Sept. 11] Available from:

Kompella A, Gampa VK, Annadasu A, Ganganamoni S, Konakanchi DP, Muddasani, PR, Nannapaneni VC. An improved process for the preparation of cabozantinib and its pharmaceutically acceptable salts thereof. PCT/IN2019/050432. Publication Date: 12.12.2019. [cited 2022 Sept. 11] Available from:

Eyring MB. Spectroscopy in Forensic Science, Editor(s): Meyers RA, Encyclopedia of Physical Science and Technology (Third Edition), Academic Press, 2003; 637-643. doi:

Öztürk B, Ankan A, Özdemir D. Olive Oil Adulteration with Sunflower and Corn Oil Using Molecular Fluorescence Spectroscopy. Editor(s): Preedy VR, Watson RR. Olives and Olive Oil in Health and Disease Prevention, Academic Press, 2010; 451-461. doi:

Darwish HW, Abdelhameed AS, Bakheita AH, Alanazi AM. A new method to determine the new C-Met inhibitor “Cabozantinib” in dosage form and human plasma via micelle-enhanced spectrofluorimetry. RSC Adv, 2015;5: 40484-40490. doi:

Coskun O. Separation techniques: Chromatography. North Clin Istanb. 2016;3(2):156-160. doi: 10.14744/nci.2016.32757. PMID: 28058406.

Shrivastava A, Mittal A. A Mini Review on Characteristics and Analytical Methods of Otilonium Bromide. Crit Rev Anal Chem. 2022;52(7):1717-1725. doi: 10.1080/10408347.2021.1913983. PMID: 34039224.

Wu C, Xu X, Feng C, Shi Y, Liu W, Zhu X, Zhang J. Degradation kinetics study of cabozantinib by a novel stability-indicating LC method and identification of its major degradation products by LC/TOF-MS and LC-MS/MS. J Pharm Biomed Anal. 2014;98:356-63. doi: 10.1016/j.jpba.2014.06.008. PMID: 24992215.

Wang X, Wang S, Lin F, Zhang Q, Chen H, Wang X, Wen C, Ma J, Hu L. Pharmacokinetics and tissue distribution model of cabozantinib in rat determined by UPLC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2015;983-984:125-31. DOI: 10.1016/j.jchromb.2015.01.020. PMID: 25638029.

Su Q, Li J, Ji X, Li J, Zhou T, Lu W, Li L. An LC-MS/MS method for the quantitation of cabozantinib in rat plasma: application to a pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci. 2015;985:119-23. doi: 10.1016/j.jchromb.2015.01.024. PMID: 25678398.

Nguyen L, Holland J, Miles D, Engel C, Benrimoh N, O'Reilly T, Lacy S. Pharmacokinetic (PK) drug interaction studies of cabozantinib: Effect of CYP3A inducer rifampin and inhibitor ketoconazole on cabozantinib plasma PK and effect of cabozantinib on CYP2C8 probe substrate rosiglitazone plasma PK. J Clin Pharmacol. 2015;55(9):1012-23. doi: 10.1002/jcph.510. PMID: 25854986.

Nguyen L, Holland J, Mamelok R, Laberge MK, Grenier J, Swearingen D, Armas D, Lacy S. Evaluation of the effect of food and gastric pH on the single-dose pharmacokinetics of cabozantinib in healthy adult subjects. J Clin Pharmacol. 2015;55(11):1293-302. doi: 10.1002/jcph.526. PMID: 25907407.

Kadi AA, Abdelhameed AS, Darwish HW, Attwa MW, Bakheit AH. Liquid chromatographic-tandem mass spectrometric assay for simultaneous quantitation of tofacitinib, cabozantinib and afatinib in human plasma and urine. Trop. J. Pharm. Res. 2016; 15(12): 2683-2692. doi:

Abdelhameed AS, Attwa MW, Kadi AA. An LC-MS/MS method for rapid and sensitive high-throughput simultaneous determination of various protein kinase inhibitors in human plasma. Biomed Chromatogr. 2017 Feb;31(2). doi: 10.1002/bmc.3793. PMID: 27450926.

Gorja A, Sumanta M. Stability-indicating method development and validation for the estimation of cabozantinib in pharmaceutical dosage forms by ultra-performance liquid chromatography. Asian J Pharm Clin Res, 2018;11(10): 238-241.

Ren LJ, Wu HJ, Sun LH, Xu X, Mo LY, Zhang L, Zhang JY, Wu CY. A sensitive LC-MS/MS method for simultaneous determination of cabozantinib and its metabolite cabozantinib N-oxide in rat plasma and its application in a pharmacokinetic study. Biomed Chromatogr. 2018;32(7):e4227. doi: 10.1002/bmc.4227. PMID: 29500905.

Inturi S, Avula PR. A sensitive bioanalytical method development and validation of cabozantinib in human plasma by LC-ESI-MS/MS. Braz. J. Pharm. Sci. 2018: 54(2):e17163. doi:

Kuna AK, Seru G, Radha GV. A novel RP- HPLC method for the quantification of cabozantinib in active pharmaceutical ingredients and pharmaceutical dosage forms. Int J Pharm Sci & Res 2019; 10(8): 3963-69. doi: 10.13040/IJPSR.0975-8232.10(8).3963-69.

Pravallika KE, Avula PR. Method development and validation for simultaneous estimation of cabozantinib and nivolumab in rat plasma by HPLC. Int J Pharm Sci Rev Res., 2020;61(2): 8-12.

Krens SD, van der Meulen E, Jansman FGA, Burger DM, van Erp NP. Quantification of cobimetinib, cabozantinib, dabrafenib, niraparib, olaparib, vemurafenib, regorafenib and its metabolite regorafenib M2 in human plasma by UPLC-MS/MS. Biomed Chromatogr. 2020;34(3):e4758. doi: 10.1002/bmc.4758. PMID: 31758580.

Qi,X, Zhang S, Yu M, Khan S. Concurrent detection of cabozantinib as an anticancer agent and its major metabolites in human serum using fluorescence-coupled micellar liquid chromatography. Arab. J. Chem., 2021;14(7): 103206. doi:10.1016/j.arabjc.2021.103206.

Chaudhary AA, Shelke AV, Jadhav AG. Development and validation of RP-HPLC Method of Cabozantinib in active pharmaceutical ingredient and pharmaceutical dosage form. J. Pharm. Res. Int. 33(11): 81-90, 2021.

Alam P, Salem-Bekhit MM, Al-Joufi FA, Alqarni MH, Shakeel F. Quantitative analysis of cabozantinib in pharmaceutical dosage forms using green RP-HPTLC and green NP-HPTLC methods: A comparative evaluation. Sustain. Chem. Pharm., 2021;21:100413.

Satyadev TNVSS. A new selective separation method development and validation of cabozantinib and nivolumab using HPLC. J. Pharm. Sci. & Res. 2021;13(3):188-192.

Podili B, Seelam M, Kammela PR. A Simple Reversed Phase High Performance Liquid Chromatography Method for the Estimation of Related Substances, Assay of Cabozantinib and Nivolumab and its Application to Dissolution Studies. Indian J Pharm Sci 2021;83(4):701-713. doi: 10.36468/pharmaceutical-sciences.821.

Venkateshwarlu P, Patel MM. Method development and validation of cabozantinib by LC-MS/MS. Pharmacia 2022;69(2): 407-413. doi:

Shrivastava, A. Characteristics and Analytical Methods of Novel PDE5 Inhibitor Avanafil: An Update. Hacet. Univ. J. Fac. Pharm., 2022;42(2): 134-147. doi: 10.52794/hujpharm.1017182.

Ivanovna KL, Sergeevich BO, Vladimirovna KO. Validation of the spectrophotometric method for the determination of quantitative composition of S-2,6-diagenoxic acid of 3-methyl-1,2,4-triazolyl- 5-thioacetate. Asian J Pharm Clin Res 2018;11(9): 91-94. doi:10.22159/ajpcr.2018.v11i9.26684.

Bandla J, Ganapaty S. New stability-indicating ultra-performance liquid chromatography method development and validation of Lenvatinib mesylate in bulk drug and pharmaceutical dosage forms. Asian J Pharm Clin Res, 2018; 11(9): 140-3. doi:10.22159/ajpcr.2018.v11i9.26766.

Mahajan NS. Deshmukh MF. Degradation kinetics of carvedilol pharmaceutical dosage forms (tablets) through stress degradation study. Int J Curr Pharm. 2022;14(1): 54-59. doi:10.22159/ijcpr.2022v14i1.44112.

Choppella V, Badipati RBKS, Gonthina H, Chukka VK. Stability indicating method development and validation for simultaneous quantification of sorafenib and regorafenib drug substances by using RP-UPLC. Int J Curr Pharm. 2020;12(1):56-62. doi:10.22159/ijcpr.2020v12i1.36832.

Beg S, Rahman M. Analytical quality by design for liquid chromatographic method development, Editor(s): Beg S, Hasnain MS, Rahman M, Almalki WH, Handbook of Analytical Quality by Design, Academic Press, 2021, 87-97. doi:

Sajid M, Płotka-Wasylka J. Green analytical chemistry metrics: A review. Talanta. 2022;238(Pt 2):123046. doi: 10.1016/j.talanta.2021.123046.



How to Cite




Review Article(s)